Pramlintide is not appropriate for patients with: Gastroparesis or other conditions causing delayed gastric emptying, as the drug's mechanism of action could worsen this Hypoglycaemia unawareness, due to the risk of compounding insulin-related hypoglycaemia Poor adherence to insulin therapy or self-monitoring of blood glucose In the UK context, NICE guidelines for type 1 diabetes (NG17) and type 2 diabetes (NG28) do not include pramlintide within their recommended treatment pathways
Alignment metrics were generated using the Genome Analysis Toolkit (GATK)s CollectAlignmentSummaryMetrics
One of the pharmacological effects of all-trans retinoic acid (ATRA), a classic anti-cancer drug, is to downregulate LSH expression and promote ferroptosis in cancer cells 167
This is a common cost-containment strategy used by many insurance companies
EMA (2024)
The Modern Peptides team can help with product documentation, secure checkout, order status, tracking, and account questions through live chat, email, or phone